Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...

The GLP-1 drugmaker recorded $26.0M of net income compared to only $1.2M in Q4 2023, thanks mainly to a ~95% YoY rise in its revenue, which reached $481.1M, exceeding the consensus by $10.6M.

In response to the news, BofA analyst Allen Lutz maintained an Underperform rating and a price target of $21.00, citing the news as a "clear negative" for Hims&Hers' GLP-1 opportunity. The analyst ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Weight management drugs may sound like a quick solve – but there are plently of everyday lifestyle changes that you can make ...

By being educated about the risks associated with obesity and pregnancy, you can take some powerful steps today to begin ...

Uncover the surprising ways fiber supports heart health brain function weight control and disease prevention beyond digestion ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...